Jesús Zurdo

Developability assessment as an early de-risking tool for biopharmaceutical development

J. Zurdo, Jesús Zurdo, 2013 .

Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case.

Salvador Ventura, Fabrizio Chiti, Francesc X Aviles, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Early Implementation of QbD in Biopharmaceutical Development: A Practical Example

Olga Obrezanova, Andreas Arnell, Thomas R. A. Gallagher, 2015, BioMed research international.

A highly amyloidogenic region of hen lysozyme.

Angelo Fontana, Christopher M Dobson, C. Dobson, 2004, Journal of molecular biology.

Exploring amyloid formation by a de novo design.

Christopher M Dobson, Shirley A Müller, C. Dobson, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Cryo‐electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing

Elena Orlova, C. Dobson, E. Orlova, 1999, The EMBO journal.

Aggregation risk prediction for antibodies and its application to biotherapeutic development

Olga Obrezanova, Andreas Arnell, J. Zurdo, 2015, mAbs.

Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases.

Michele Vendruscolo, Fabrizio Chiti, Christopher M Dobson, 2005, Journal of molecular biology.

Molecular recycling within amyloid fibrils

Christopher M. Dobson, Ernest Giralt, Carol V. Robinson, 2005, Nature.

Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains.

Michele Vendruscolo, Fabrizio Chiti, Christopher M Dobson, 2004, Journal of molecular biology.

De novo designed peptide-based amyloid fibrils

Andreas Hoenger, Luis Serrano, Christopher M Dobson, 2002, Proceedings of the National Academy of Sciences of the United States of America.